Randomized phase II study of daily and alternate-day administration of S-1 for adjuvant chemotherapy in completely-resected stage I non-small cell lung cancer: results of the Setouchi Lung Cancer Group Study 1301

BACKGROUND: The aim of this multicenter, randomized phase II study was to analyze the feasibility and safety of alternate-day S-1, an oral fluoropyrimidine, for adjuvant chemotherapy in patients with completely resected pathological stage I (tumor diameter > 2 cm) non-small cell lung cancer (NSCL...

Descripción completa

Detalles Bibliográficos
Autores principales: Okumura, Norihito, Soh, Junichi, Suzuki, Hiroyuki, Nakata, Masao, Fujiwara, Toshiya, Nakamura, Hiroshige, Sonobe, Makoto, Fujinaga, Takuji, Kataoka, Kazuhiko, Gemba, Kenichi, Kataoka, Masafumi, Hotta, Katsuyuki, Yoshioka, Hiroshige, Matsuo, Keitaro, Sakamoto, Junichi, Date, Hiroshi, Toyooka, Shinichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101150/
https://www.ncbi.nlm.nih.gov/pubmed/33957881
http://dx.doi.org/10.1186/s12885-021-08232-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8101150/
https://www.ncbi.nlm.nih.gov/pubmed/33957881
http://dx.doi.org/10.1186/s12885-021-08232-6

Ejemplares similares